Search Results - "Danzon, Patricia M."

Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] by Lakdawalla, Darius N., Doshi, Jalpa A., Garrison, Louis P., Phelps, Charles E., Basu, Anirban, Danzon, Patricia M.

“…The third section of our Special Task Force report identifies and defines a series of elements that warrant consideration in value assessments of medical…”
Get full text

International Prices And Availability Of Pharmaceuticals In 2005 by Danzon, Patricia M, Furukawa, Michael F

“…This paper compares pharmaceutical spending, availability, use, and prices in twelve countries in 2005. Drug spending per capita was higher in the United…”
Get full text

The impact of price regulation on the launch delay of new drugs-evidence from twenty-five major markets in the 1990s by Danzon, Patricia M., Wang, Y. Richard, Wang, Liang

“…We analyze the effect of price regulation on delays in launch of new drugs. Because a low price in one market may ‘spill‐over’ to other markets, through…”
Get full text

Mergers and acquisitions in the pharmaceutical and biotech industries by Danzon, Patricia M., Epstein, Andrew, Nicholson, Sean

“…We examine the determinants and effects of M&A activity in the pharmaceutical/biotechnology industry using SDC data on 383 firms from 1988 to 2001. For large…”
Get full text

Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances by Danzon, Patricia M., Nicholson, Sean, Pereira, Nuno Sousa

“…Using data on over 900 firms for the period 1988–2000, we estimate the effect on phase-specific biotech and pharmaceutical R&D success rates of a firm's…”
Get full text

Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues by Danzon, Patricia M.

“…Differential pricing—manufacturers varying prices for on-patent pharmaceuticals across markets—can, in theory, lead to increased patient access and improved…”
Get full text

Prices And Availability Of Biopharmaceuticals: An International Comparison by Danzon, Patricia M, Furukawa, Michael F

“…This paper presents new evidence on availability, use, and prices of biopharmaceuticals in five major European Union (EU) markets, Canada, Australia, Japan,…”
Get full text

Drug Pricing and Value in Oncology by Danzon, Patricia M

“…This paper first reviews the evidence on price levels, price growth, and value for cancer drugs. The available evidence suggests that prices for originator…”
Get more information

Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5] by Phelps, Charles E., Lakdawalla, Darius N., Basu, Anirban, Drummond, Michael F., Towse, Adrian, Danzon, Patricia M.

“…The fifth section of our Special Task Force report identifies and discusses two aggregation issues: 1) aggregation of cost and benefit information across…”
Get full text

Does Regulation Drive Out Competition in Pharmaceutical Markets? by Danzon, Patricia M., Chao, Li‐Wei

“…Most countries regulate pharmaceutical prices, either directly or indirectly, on the assumption that competition is at best weak in this industry. This paper…”
Get full text

Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report [4] by Danzon, Patricia M., Drummond, Michael F., Towse, Adrian, Pauly, Mark V.

“…The fourth section of our Special Task Force report focuses on a health plan or payer’s technology adoption or reimbursement decision, given the array of…”
Get full text

Cross-national price differences for pharmaceuticals: how large, and why? by Danzon, Patricia M., Chao, Li-Wei

“…Bilateral drug price and quantity indexes, based on comprehensive data for seven countries (US, Canada, France, Germany, Italy, Japan and the UK), refute the…”
Get full text

Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures by Danzon, Patricia M.

“…To analyze how value-based pricing (VBP), which grounds the price paid for pharmaceuticals in their value, can manage “affordability” challenges, defined as…”
Get full text

A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7] by Garrison, Louis P., Neumann, Peter J., Willke, Richard J., Basu, Anirban, Danzon, Patricia M., Doshi, Jalpa A., Drummond, Michael F., Lakdawalla, Darius N., Pauly, Mark V., Phelps, Charles E., Ramsey, Scott D., Towse, Adrian, Weinstein, Milton C.

“…This summary section first lists key points from each of the six sections of the report, followed by six key recommendations. The Special Task Force chose to…”
Get full text

Biotech‐Pharmaceutical Alliances as a Signal of Asset and Firm Quality by Nicholson, Sean, Danzon, Patricia M., McCullough, Jeffrey

“…We examine the determinants of biotech‐pharmaceutical alliance prices to determine whether the market for alliances is characterized by asymmetric information…”
Get full text

A general model of the impact of absenteeism on employers and employees by Pauly, Mark V., Nicholson, Sean, Xu, Judy, Polsky, Dan, Danzon, Patricia M., Murray, James F., Berger, Marc L.

“…Most studies on the indirect costs of an illness and the cost effectiveness of a medical intervention or employer‐sponsored wellness program assume that the…”
Get full text

Drug Pricing and Value in Oncology by Danzon, Patricia M., Taylor, Erin

“…This paper examines the issue of prices, relative to value, for cancer drugs. The analysis focuses on the effects on manufacturer pricing incentives of…”
Get full text

Specific Value Assessment Considerations by Kamal-Bahl, Sachin, Towse, Adrian, Spurgin, Liz, Danzon, Patricia M.

“…A session focused on value measures appropriate for specific decision and pricing contexts is presented. Indication-based pricing (IBP) or indication-specific…”
Get full text

Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement by Danzon, Patricia M., Mulcahy, Andrew W., Towse, Adrian K.

“…This paper analyzes determinants of ex‐manufacturer prices for originator and generic drugs across countries. We focus on drugs to treat HIV/AIDS, TB, and…”
Get full text

Price, Financial Quality, and Capital Flows in Insurance Markets by Cummins, J.David, Danzon, Patricia M.

“…This paper develops a model of price determination in insurance markets. Insurance is provided by firms that are subject to default risk. Demand for insurance…”
Get full text